MetaStat Spotlighted in Three Publications
October 27 2014 - 6:30AM
Business Wire
Company’s Diagnostic Tests for Early Detection
of Systemic Metastasis Spotlighted in Boston Magazine, Medical
Device Daily and MedCity News
MetaStat, Inc. (OTCQB:MTST), a molecular diagnostic company
focused on understanding and treating systemic metastasis, was the
subject of recent articles in Boston Magazine, Medical Device Daily
and MedCity News.
The Boston Magazine article, “Boston Company To Introduce New
Breast Cancer Diagnosis Tool,” focuses on the MetaSite Breast
test’s potential to give doctors the ability to differentiate
between metastatic and non-metastatic breast cancers, and
eventually other types of cancer as well.
The Medical Device Daily article, “NewCo on the Go: MetaStat’s
summer: new financing, spin-off, and positive study results,”
describes the Company’s recent equity financing, reports the
spinoff of its therapeutic assets and notes that positive results
from a MetaSite Breast study were published in the Journal of the
National Cancer Institute.
The MedCity News article, “Diagnostics company uses epigenetics
principles to develop metastatic breast cancer test,” discusses how
studies of the tumor microenvironment, along with an understanding
of the function of the Mena protein, have allowed MetaStat to
refine its diagnostic tests.
To read the Boston Magazine article, please visit the following
link:
www.bostonmagazine.com/health/blog/2014/10/21/metastat-breast-cancer-diagnosis/
To read the Medical Device Daily article, please visit the
following link:
www.medicaldevicedaily.com/servlet/com.accumedia.web.Dispatcher?next=bioWorldHeadlines_article&forceid=87394
To read the MedCity News article, please visit the following
link:
www.medcitynews.com/2014/09/diagnostics-company-uses-epigenetics-principles-develop-metastatic-breast-cancer-test/
About MetaStat, Inc.
MetaStat, Inc (MTST) is a molecular diagnostic company that
develops and commercializes diagnostic tests for early and reliable
prediction of systemic metastasis, the process by which cancer
spreads from a primary tumor through the bloodstream to other areas
of the body. MetaStat is focused on breast, prostate, lung and
colorectal cancers, where systemic metastasis is responsible for
approximately 90% of all deaths. The Company’s function-based
diagnostic platform technology is based on the identification and
understanding of the pivotal role of the mena protein and its
isoforms, a common pathway for the development of systemic
metastatic disease in all epithelial-based solid tumors. Both the
MetaSite Breast™ and MenaCalc™ assays are designed to accurately
stratify patients based on their individual risk of metastasis and
to provide physicians with clinically actionable information to
better "customize" cancer treatment. MetaStat’s testing platform
improves treatment planning decisions by positively identifying
patients with a high-risk of metastasis who need aggressive therapy
and by sparing patients with a low-risk of metastasis from the
harmful side effects and expense of chemotherapy. The company is
based in Boston.
Forward-Looking Statements
This press release contains "forward-looking statements" within
the meaning of Section 27A of the Securities Act of 1933, as
amended, and Section 21E of the Securities Exchange Act of 1934, as
amended, and such forward-looking statements are made pursuant to
the safe harbor provisions of the Private Securities Litigation
Reform Act of 1995. You are cautioned that such statements are
subject to a multitude of risks and uncertainties that could cause
future circumstances, events or results to differ materially from
those projected in the forward-looking statements as a result of
various factors and other risks, including those set forth in the
Company's Form 10-K filed with the Securities and Exchange
Commission. You should consider these factors in evaluating the
forward-looking statements included herein, and not place undue
reliance on such statements. The forward-looking statements in this
release are made as of the date hereof and the company undertakes
no obligation to update such statements.
Media:Dian Griesel Int’l. for MetaStatSusan Forman,
212-825-3210sforman@dgicomm.comorInvestors:MetaStat,
Inc.Daniel Schneiderman, 212-608-0827Vice
Presidentdan@metastat.com
MetaStat (CE) (USOTC:MTST)
Historical Stock Chart
From Sep 2024 to Oct 2024
MetaStat (CE) (USOTC:MTST)
Historical Stock Chart
From Oct 2023 to Oct 2024
